Matthew A. Spinelli

Plasma-based antigen persistence in the post-acute phase of COVID-19

Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir–Rilpivirine in People With HIV Who Are Virally Unsuppressed

Preexposure Prophylaxis (PrEP) for HIV

Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

Chronic viral coinfections differentially affect the likelihood of developing long COVID

COVID-19 Outcomes and Risk Factors Among People Living with HIV

Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection

Promises and challenges: cabotegravir for preexposure prophylaxis

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study

Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement

Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity

Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study

The interplay between HIV and COVID-19: summary of the data and responses to date

Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions

Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19

Understanding PrEP Persistence: Provider and Patient Perspectives

Missed opportunities to prevent HIV infections among pre‐exposure prophylaxis users: a population‐based mixed methods study, San Francisco, United States

Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test

Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics

Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings

Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network

Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence

Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System

High Interest in Doxycycline for Sexually Transmitted Infection Postexposure Prophylaxis in a Multicity Survey of Men Who Have Sex With Men Using a Social Networking Application

Food Insecurity is Associated with Poor HIV Outcomes Among Women in the United States

Factors Associated with Substance Use in Older Homeless Adults: Results from the Hope Home Study